Navigation Links
Orexigen(R) Therapeutics Announces In-Licensing of Key Patents to Further Strengthen its Intellectual Property Estate for Contrave(R)
Date:6/11/2009

SAN DIEGO, June 11 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced the licensing of certain intellectual property (IP) from GlaxoSmithKline (GSK) that expands the Company's IP position underlying Contrave, its lead product candidate for the treatment of obesity.

"This license agreement with GSK complements the IP foundation of Contrave, providing us with additional product formulation options as we pursue regulatory approval and potential commercialization of Contrave," said Michael Narachi, President and Chief Executive Officer, Orexigen Therapeutics.

In exchange for undisclosed upfront and future milestone payments, Orexigen secured non-exclusive rights to certain formulation patents related to bupropion, one of the constituents of Contrave. The transaction is not expected to materially impact the Company's financial position. Top line results of the first of four Phase 3 clinical trials for Contrave, NB-302, were announced January 2009. Results from the three other Phase 3 clinical trials (NB-301, NB-303, NB-304) are expected to be announced in the third quarter of 2009. Pending positive results, the Company is on track to submit a New Drug Application (NDA) with the FDA in the first half of 2010.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the scope and duration of intellectual property protection for Contrave, the timing of completion and announcement of results for the remaining Phase 3 clinical trials for Contrave, the potential for, and timing of, an NDA submission for Contrave, the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave, the potential to commercialize Contrave and the expected impact of the license agreement with GSK on Orexigen's financial position. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen and its licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of Contrave; the final analyses of data from the remaining clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials, and the FDA may not agree with the Company's interpretation of efficacy and safety results; earlier clinical trials may not be predictive of future results; Contrave may not receive regulatory approval on a timely basis or at all, and the FDA may require Orexigen to complete additional clinical, non-clinical or other requirements prior to the submission or the approval of NDAs for either product candidate; the potential for adverse safety findings relating to Contrave to delay or prevent regulatory approval or commercialization, or result in product liability claims; the third parties on whom Orexigen relies to assist with the development programs for Contrave, including clinical investigators, contract laboratories, clinical research organizations and manufacturing organizations, may not successfully carry out their contractual duties or obligations or meet expected deadlines, and the quality or accuracy of the data or materials generated by such third parties may be of insufficient quality to include in the Company's regulatory submissions; and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
2. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
3. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
4. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
5. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
6. Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
7. Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants
8. Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Incs. GCS-100 Molecule
9. Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers
10. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
11. Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 2017 , ... “The Trials I Face to Receive God’s Grace”: a ... aspirations and goals to better one’s life through God. “The Trials I Face to ... all the wrong places, found a love for writing. Green feels that expressing his ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... gathering of executive marketers this week about the value of senior executives, pointed ... that has happened in business has brought us to the present and will ...
(Date:9/20/2017)... ... September 20, 2017 , ... “They Sang At Her Funeral”: a ... murderer starts revealing the skeletons in their closets. “They Sang At Her Funeral” is ... fifty-six years young and married with five children and twelve grandchildren. Before becoming a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... addition of strategic marketing leader, Denise Flannery, to its strategic advisory and client ... Management Consultant, Denise will work with clients across different industries to develop and ...
(Date:9/19/2017)... , ... September 19, 2017 ... ... that Scott McFarland has joined its executive team as the President of ... innovative value-based care management systems and contact centers. , “Scott is a ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... 6, 2017  Medical professionals are expected ... while treating their patients. Medical simulations offer ... involving patients. Simulation provides a safe method ... out procedures, refine techniques and build confidence, ... new technology, such as augmented reality, will ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a ... created a vibrant charitable donation program -- "Color ... support congenital heart defect research by The Children,s ... and the general public are encouraged to download ... submit the completed artwork to the gallery on ...
Breaking Medicine Technology: